WEDNESDAY, April 3, 2024 -- Tildrakizumab is efficacious for patients with moderate-to-severe plaque psoriasis affecting the scalp, according to a study published online March 28 in the Journal of the American Academy of Dermatology.

Kurt Gebauer, M.B.B.S., from Fremantle Dermatology in Australia, and colleagues examined the efficacy and safety of tildrakizumab in a phase 3b randomized study involving patients with moderate-to-severe plaque psoriasis affecting the scalp. Overall, 89 patients were treated with tildrakizumab 100 mg and 82 with placebo at weeks 0 and 4.

The researchers found that 49.4 and 7.3 percent of those receiving tildrakizumab and placebo, respectively, achieved an Investigator Global Assessment modified 2011 (scalp) response (score of clear or almost clear with ≥2-point reduction from baseline) at week 16 and 46.1 and 4.9 percent, respectively, achieved a response at week 12. Overall, 60.7 versus 4.9 percent and 48.3 versus 2.4 percent achieved Psoriasis Scalp Severity Index 90 response at weeks 16 and 12, respectively. There were no serious treatment-related adverse events reported.

"Tildrakizumab 100 mg is efficacious and improves patient-reported scalp itch and quality of life compared with placebo, with no new safety signals," the authors write.

Several authors disclosed ties to pharmaceutical companies, including Sun Pharma, which manufactures tildrakizumab and funded the study.